Sanofi: agreement for acquisition of Ablynx
(CercleFinance.com) - Sanofi has announced a final agreement with Ablynx, whereby it has offered to acquire this biopharmaceutical company specialising in the discovery and development of nanobodies, a transaction that has been unanimously approved by the boards of directors.
The pharmaceutical giant has offered to buy back all of Ablynx's ordinary shares, warrants and convertible bonds in circulation for a price of 45 euros per share in cash, valuing Ablynx at 3.9 billion euros (on a fully diluted basis).
After considering R&D expenses, the acquisition is expected to have a neutral impact on EPS of businesses in 2018 and 2019. Subject to satisfaction or waiver of the usual terms, it should be finalised by the end of the second quarter of 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The pharmaceutical giant has offered to buy back all of Ablynx's ordinary shares, warrants and convertible bonds in circulation for a price of 45 euros per share in cash, valuing Ablynx at 3.9 billion euros (on a fully diluted basis).
After considering R&D expenses, the acquisition is expected to have a neutral impact on EPS of businesses in 2018 and 2019. Subject to satisfaction or waiver of the usual terms, it should be finalised by the end of the second quarter of 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.